Member Info for GlenFidrich

Then why, at the time, did Dr Reader state: "The results from our Covid-19 research project are very encouraging and provide clear evidence of the potential of SDC-1801 to reduce the excessive inflammatory response seen in severe Covid-19. We are keen to progress this project to the next stage and will now explore our options to find the best way to fund these next steps. This could include the UK government's AGILE clinical development platform, which was established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development plan targeting autoimmune diseases. We look forward to providing updates on our progress as we reach key milestones in the development of SDC-1801."? I feel that we were misled on AGILE, and on the "orderly queue" comment (whether off the cuff, or not). Both statements caused the share price to spike, but in the end led to nought. I think shareholders deserve better, is all I'm saying.

Spondulicks, that all sounds plausible, until we cast our minds back to 2020, and the "pressing need for urgent treatments" at that time. https://www.lse.co.uk/rns/SAR/notification-of-grant-award-for-covid-19-research-4faw31mw6ncledl.html

As you will see, Sareum were awarded a grant of "£174,000 ...(the 'Grant') by UK Research & Innovation ('UKRI') to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in severe phase Covid-19". This was great news, especially for the share price. Then, in July 2021, we were told that the "completed Covid-19 research project had delivered encouraging results". https://www.lse.co.uk/rns/SAR/covid-19-research-project-results-j5q89njlqb68nqx.html "The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor." Wow, I hear you say. There was also talk (from Dr Reader) of joining the AGILE program, established to fast forward into clinical trials precisely the sort of potential treatment that had shown such promise in their preliminary findings. The share price responded accordingly, in tandem with the HNWI investments. Then, nothing. Zilch. Nada. What happened? Talk about dropping the ball! The share price went the same way as the ball. Then, of course, Dr Parker tried to reassure us with the "form an orderly queue" comment (re: SRA 737) which helped the share price recover somewhat (from 70p to 140p over a relatively short period). Again, what happened? And then came RF (an awful solution to a glaring funding issue), which brings us to now. I'm not for changing the board. But, at the same time, I don't particularly like being misled. So, Spondulicks, whilst I echo your comments regarding the pressing need for a potential treatment for the latest bad news coming out of China, do you seriously think our board are capable of riding to the rescue? I would love to believe so, but past history doesn't really inspire confidence.

Fanti, you think increasing our interest in SRA737 to 50%, thereby actively "controlling, marketing, and commercializing the asset" is realistic? Therein lies the problem, I'm afraid. The science seems robust, but the business acumen would appear non-existent. Dr Parker claimed at last year's AGM that it was a case of "form an orderly queue" when it came to active interest in SRA737. So what happened?

Bushy, for some reason (maybe Egypt's proximity to the whole Gaza mess), Centamin seems to be lagging other miners in the sector (see https://www.google.com/finance/quote/HOC:LON?hl=en&comparison=LON%3ACEY&window=1Y ). With gold near, or at, all-time highs in most currencies, one wonders what's holding Centamin back. 159p would appear a tad optimistic near term, but 120-130p should be doable when the market finally wakes up.

GDR have a similar arrangement with RF, and each time they have drawn down on their facility it has warranted an RNS. I'm not sure if it's a formal requirement or merely a heads up from the GDR board. Interestingly, their SP has similarly nosedived since RF became involved.

Https://news.sky.com/story/uk-to-rejoin-eu-horizon-programme-in-bespoke-new-agreement-12956520

I always wondered whether MHRA's refusal to authorize Sareum's CTA was connected to the fact the UK was outside of the EU, and hadn't yet figured out its own protocols for CTAs. All probably ancient history now, although might it have a positive impact on any future CTA re: SDC-1802?

I'm holding on. This looks like it may have legs. But my time horizon may be longer than some. Don't forget that this was over 300p in 2020 and near 600p in 2011. Buy and hold for me, but each to their own.

Cj, I suggest you read the thread:

Moon: "Well there is mention of covid lockdown again if it happen price gold silver go though the roof"

You: "Moon. It didn't in 2020. Why would it now?"

Me: "Cj, in fairness to Mr Moon, silver more than doubled between March 2020 and September 2020, and gold added roughly 35% in that time, also. A UK-wide lockdown was announced on 23rd March, 2020."

You: "Glen 'silver more than doubled between March 2020 and September 2020'. 2020 was the peak of the lock down. Silver doubled during that period."

I fail to see your point. You're just reiterating what I said, but insinuating I'm somehow wrong. All very bizarre. Keep taking the tablets, cj!

Cj, in fairness to Mr Moon, silver more than doubled between March 2020 and September 2020, and gold added roughly 35% in that time, also. A UK-wide lockdown was announced on 23rd March, 2020.

...is when there's blood in the streets." Well, after the recent carnage, are we there yet?

This is all well and good, but the market remains underwhelmed. Does anyone know the likely terms of the agreement? Will it involve yet more dilution? Plus, this bit in the RNS seems to contradict itself:

"The pricing submitted by REGROUP's bid supports:

o The potential for capital savings when compared to those forecasted in the scoping study; and

o It is consistent with the assumptions made by the Scoping Study to deliver direct cost of production of approximately US$60 per tonne". Either there are capital savings (compared to the scoping study forecast), or the cost is consistent with what the scoping study assumed. You can't have it both ways, surely, or am I being thick?

Silver catching a bid today (up nearly 3% in GBP terms). Also, the BRICS summit (22nd-24th) may throw up some surprises? In addition, the bond market imploding should be good for gold? Probably other reasons, too.

Dickie, normally I would agree with you. But I think many LTHs here are so far under water that selling now would be counter-productive. Moreover, I think they do have every right to question the integrity of the board, given the missed deadlines and broken assurances, and continued cash calls, that collectively dilute the real supporters of UFO who, frankly, deserve better.

Sflf, I guess this morning's RNS answers your question: "Full safety data from the Phase 1a trial are expected to be available during the first half of 2024 and, provided satisfactory results continue to be obtained, and funding is available under the RiverFort Equity Prepayment Facility or otherwise, a Phase 1b clinical study is expected to commence as soon as possible thereafter in psoriasis patients, with a readout expected before the end of 2024, subject to recruitment and progress."

May the Lord be with you, Bish. You certainly must possess almighty cojones...

"Physician heal thyself"? Pompous twat.

Mr Magoo?

Apologies if this has already been covered, but what happened to the "there is a key Native Title meeting scheduled in July" (from the Financial Results RNS of 30th June)? Has is happened? Was it re-scheduled? Anyone? Starting to get a tad unnerved by the missed deadlines and poor comms. I do think shareholders have a right to know if there are delays to published timelines, even if the delays are not of UFO's making. A little more transparency would be nice.

Wasn't it Mao who said: "The more one reads, the stupider one becomes"? I think @tacet is living proof of that particular maxim.

...on days like today often reveal the true story. Do they, for example, indicate a wholesale exodus? No. I know the buy/sell figures on this website are unreliable, but the volume of shares (whether bought or sold - who's counting?) suggests only around 5% of shares in issue have exchanged hands, so far. Yet we're down 32%? That seems an overreaction, surely? At these levels, you'll likely make 25% return in short order as the market comes to its senses. And delays/"additional information required" are really not uncommon when trialling new drugs. I expect this to be a storm in a teacup and anything requiring further detail to be clarified forthwith. Markets hate uncertainty/surprises. I get it. But invariably the market has its hissy fit, realizes it overreacted, and boom, we're back to 2p awaiting news.